Literature DB >> 19717473

Functional analysis of 5-lipoxygenase promoter repeat variants.

Susanna Vikman1, Romulo M Brena, Patrice Armstrong, Jaana Hartiala, Charles B Stephensen, Hooman Allayee.   

Abstract

Variants of a hexanucleotide repeat polymorphism in the promoter of the 5-lipoxygenase (5-LO) gene have been associated with cardiovascular disease traits in humans, which may be due, at least in part, to differential expression of the at-risk alleles. To more fully characterize these variants, we carried out gene expression and DNA methylation studies in primary leukocytes from healthy individuals carrying various 5-LO promoter alleles. Regardless of genotype, 5-LO and 5-LO-activating protein (FLAP) gene expression was higher in granulocytes compared with monocytes and lymphocytes, whereas leukotriene A4 hydrolase (LTA4H) expression was higher in monocytes. In all three leukocyte populations, 5-LO mRNA levels were positively correlated with those of FLAP and LTA4H, with the highest correlation observed in granulocytes. In lymphocytes, individuals homozygous for the shorter 3 and 4 repeat alleles had between 20-35% higher 5-LO, FLAP and LTA4H expression compared with homozygous carriers of the wild-type 5 repeat allele (P = 0.03-0.0001). DNA methylation analysis of four CpG islands in a 1500 bp region encompassing the 5-LO promoter and the first approximately 100 bp of intron 1 revealed relatively low overall DNA methylation across all genotypes and leukocyte populations. However, analysis of the promoter repeats themselves demonstrated that, regardless of cell population, the 4 allele was methylated approximately twice as much as the 3 allele (P < 0.0001). Our results demonstrate that, in lymphocytes, the shorter repeat alleles of the 5-LO promoter lead to higher gene expression, which may be regulated through differential DNA methylation of the CpGs located within these repeats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19717473      PMCID: PMC2773268          DOI: 10.1093/hmg/ddp414

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  36 in total

Review 1.  The biology of 5-lipoxygenase: function, structure, and regulatory mechanisms.

Authors:  E S Silverman; J M Drazen
Journal:  Proc Assoc Am Physicians       Date:  1999 Nov-Dec

Review 2.  Arachidonate 5-lipoxygenase.

Authors:  Olof Rådmark
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

3.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.

Authors:  K H In; K Asano; D Beier; J Grobholz; P W Finn; E K Silverman; E S Silverman; T Collins; A R Fischer; T P Keith; K Serino; S W Kim; G T De Sanctis; C Yandava; A Pillari; P Rubin; J Kemp; E Israel; W Busse; D Ledford; J J Murray; A Segal; D Tinkleman; J M Drazen
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

4.  The 5-lipoxygenase promoter is regulated by DNA methylation.

Authors:  Johannes Uhl; Niko Klan; Matthias Rose; Karl-Dieter Entian; Oliver Werz; Dieter Steinhilber
Journal:  J Biol Chem       Date:  2001-11-12       Impact factor: 5.157

Review 5.  5-lipoxygenase and atherosclerosis.

Authors:  Margarete Mehrabian; Hooman Allayee
Journal:  Curr Opin Lipidol       Date:  2003-10       Impact factor: 4.776

6.  Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis.

Authors:  Rainer Spanbroek; Rolf Grabner; Katharina Lotzer; Markus Hildner; Anja Urbach; Katharina Ruhling; Michael P W Moos; Brigitte Kaiser; Tina U Cohnert; Thorsten Wahlers; Arthur Zieske; Gabriele Plenz; Horst Robenek; Peter Salbach; Hartmut Kuhn; Olof Radmark; Bengt Samuelsson; Andreas J R Habenicht
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

7.  Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis.

Authors:  David R Crosslin; Svati H Shah; Sarah C Nelson; Carol S Haynes; Jessica J Connelly; Shera Gadson; Pascal J Goldschmidt-Clermont; Jeffery M Vance; Jason Rose; Chris B Granger; David Seo; Simon G Gregory; William E Kraus; Elizabeth R Hauser
Journal:  Hum Genet       Date:  2009-01-08       Impact factor: 4.132

8.  The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.

Authors:  Anna Helgadottir; Andrei Manolescu; Gudmar Thorleifsson; Solveig Gretarsdottir; Helga Jonsdottir; Unnur Thorsteinsdottir; Nilesh J Samani; Gudmundur Gudmundsson; Struan F A Grant; Gudmundur Thorgeirsson; Sigurlaug Sveinbjornsdottir; Einar M Valdimarsson; Stefan E Matthiasson; Halldor Johannsson; Olof Gudmundsdottir; Mark E Gurney; Jesus Sainz; Margret Thorhallsdottir; Margret Andresdottir; Michael L Frigge; Eric J Topol; Augustine Kong; Vilmundur Gudnason; Hakon Hakonarson; Jeffrey R Gulcher; Kari Stefansson
Journal:  Nat Genet       Date:  2004-02-08       Impact factor: 38.330

9.  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis.

Authors:  James H Dwyer; Hooman Allayee; Kathleen M Dwyer; Jing Fan; Huiyun Wu; Rebecca Mar; Aldons J Lusis; Margarete Mehrabian
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245

10.  High sensitivity mapping of methylated cytosines.

Authors:  S J Clark; J Harrison; C L Paul; M Frommer
Journal:  Nucleic Acids Res       Date:  1994-08-11       Impact factor: 16.971

View more
  11 in total

1.  Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice.

Authors:  Hu Chen; Hari Manev
Journal:  Neuropharmacology       Date:  2010-09-22       Impact factor: 5.250

Review 2.  On the sequence-directed nature of human gene mutation: the role of genomic architecture and the local DNA sequence environment in mediating gene mutations underlying human inherited disease.

Authors:  David N Cooper; Albino Bacolla; Claude Férec; Karen M Vasquez; Hildegard Kehrer-Sawatzki; Jian-Min Chen
Journal:  Hum Mutat       Date:  2011-09-02       Impact factor: 4.878

3.  Nutrigenetic response to omega-3 fatty acids in obese asthmatics (NOOA): rationale and methods.

Authors:  Jason E Lang; Edward B Mougey; Hooman Allayee; Kathryn V Blake; Richard Lockey; Yan Gong; Jobayer Hossain; Kelleigh Killen; John J Lima
Journal:  Contemp Clin Trials       Date:  2013-01-06       Impact factor: 2.226

4.  Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans.

Authors:  Patrice Armstrong; Darshan S Kelley; John W Newman; Frank E Staggers; Janna Hartiala; Hooman Allayee; Charles B Stephensen
Journal:  J Nutr       Date:  2012-06-27       Impact factor: 4.798

5.  ALOX5 gene variants affect eicosanoid production and response to fish oil supplementation.

Authors:  Charles B Stephensen; Patrice Armstrong; John W Newman; Theresa L Pedersen; Jillian Legault; Gertrud U Schuster; Darshan Kelley; Susanna Vikman; Jaana Hartiala; Rami Nassir; Michael F Seldin; Hooman Allayee
Journal:  J Lipid Res       Date:  2011-02-04       Impact factor: 5.922

6.  5-Lipoxygenase in mouse cerebellar Purkinje cells.

Authors:  H Chen; S Dzitoyeva; H Manev
Journal:  Neuroscience       Date:  2010-09-17       Impact factor: 3.590

7.  ALOX5 polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma.

Authors:  E Mougey; J E Lang; H Allayee; W G Teague; A J Dozor; R A Wise; J J Lima
Journal:  Clin Exp Allergy       Date:  2013-05       Impact factor: 5.018

8.  Genetic contribution of the leukotriene pathway to coronary artery disease.

Authors:  Jaana Hartiala; Dalin Li; David V Conti; Susanna Vikman; Yesha Patel; W H Wilson Tang; Marie-Louise Brennan; John W Newman; Charles B Stephensen; Patrice Armstrong; Stanley L Hazen; Hooman Allayee
Journal:  Hum Genet       Date:  2011-02-04       Impact factor: 4.132

9.  Asthma in sickle cell disease: implications for treatment.

Authors:  Kathryn Blake; John Lima
Journal:  Anemia       Date:  2011-03-03

10.  Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial.

Authors:  Chinedu Nwokoro; Hitesh Pandya; Stephen Turner; Sandra Eldridge; Christopher J Griffiths; Tom Vulliamy; David Price; Marek Sanak; John W Holloway; Rossa Brugha; Lee Koh; Iain Dickson; Clare Rutterford; Jonathan Grigg
Journal:  Lancet Respir Med       Date:  2014-09-08       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.